Statement by Ecuador at June 2012 WTO TRIPS Council on copyright limitations and exceptions
This statement was delivered by Ecuador on 5 June 2012 at the WTO TRIPS Council on copyright limitations and exceptions.
CONSEJO DE LOS ADPIC
5-6 DE JUNIO DE 2012
PUNTO L. DE LA AGENDA
INTERVENCIÓN DEL ECUADORSeñor Presidente,
El Ecuador da la bienvenida a la iniciativa organizada por Brasil y Estados Unidos con respecto al punto L. sobre las limitaciones y excepciones a los derechos de autor en el marco de las negociaciones en curso en la OMPI.
Intervention of Chile to the TRIPS Council on Copyright Limitations and Exceptions
This statement was delivered by Chile on 5 June 2012 at the WTO TRIPS Council on copyright limitations and exceptions.
1 The USPTO/DOC’s liberal and misleading definition of IP-Intensive industries is designed to influence policy debates
At yesterday’s TACD event, USPTO and KEI discussed the report by the Department of Commerce’s Economics and Statistics Administration and the United States Patent and Trademark Office on Intellectual Property and employment. The report, titled: Intellectual Property and the U.S. Economy: Industries in Focus, has been widely quoted, including these bullets from its executive summary:
- IP-intensive industries accounted for about $5.06 trillion in value added, or 34.8 percent of U.S. gross domestic product (GDP), in 2010.
1 5 June 2012: India’s statement at WTO TRIPS Council: Exchange of information on securing supply chains against counterfeit goods
On 5 June 2012, India delivered the following intervention at the WTO Council for TRIPS on agenda item K, “Exchange of information on securing supply chains against counterfeit goods”.
Intervention on Agenda Item K(WHO donors) Gates Foundation, US, UK, Canada, Rotary Int., Norway and GAVI: Setting the agenda for global public health?
In preparation for the 65th World Health Assembly, held in Geneva from 21 May 2012 to 26 May 2012, the World Health Organization (WHO) prepared a document (A65/29 Add. 1, 5 April 2012) entitled “Voluntary contributions by fund and by donor for the financial period 2010-2011. Continue Reading
Recent ICE Press regarding counterfeit of pharmaceutical drugs
This is a rough list of the recent ICE press releases mentioning counterfeit and pharmaceutical. It is quite clear that the overwhelming majority of counterfeit busts involve Viagra and other erectile dysfunction drugs, a problem that will probably resolve itself once the Pfizer patents on Viagra expire.
In my quick read of the ICE press releases, I found just 12 pharmaceutical counterfeiting cases in the ICE press releases from 2009 to May 2012, with 14 defendants.
- 13 of the 14 defendants were men.
What’s a counterfeit? And how many counterfeit drugs are there?
Donald McNeil has an article in the New York Times that appeared in print on May 22, 2012 (page D6 of the New York edition) with the headline: “Malaria: Fake and Substandard Drugs Grow as Threat to Fight Disease.” A web version is available here: http://www.nytimes.com/2012/05/22/health/policy/fake-and-substandard-drugs-grow-as-threat-to-fight-malaria.html
Medical Research and Development
The following are some areas of KEI research, analysis and advocacy as regards medical research and development. More details will be added later.
Costs of development of new drugs
Reform of Incentives to Stimulate R&D
KEI provides evaluation of various incentive measures, and proposes a variety of reforms, including but not limited to those that de-link R&D costs from product prices.
De-linkage of R&D costs from product prices.
KEI Statement on WHA resolution on Consultative Expert Working Group on Research and Development: Financing and Coordination
KEI Statement on World Health Assembly resolution on Consultative Expert Working Group on Research and Development: Financing and Coordination
A number of developing countries worked together to push the World Health Assembly to create a member state process to consider the implementation of the CEWG. The most important CEWG recommendations are to begin work on a new WHO Convention on R&D financing, and to de-link R&D costs from drug prices.
1 Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health
Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health (Copy of US statement available here: https://www.keionline.org/node/1416).
May 25, 2012
To each and everyone who worked on the SCP submission:
This letter outlines our concerns to the May 23, 2012 statement to the 18th Session of the World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP), on the agenda for patents and health.
In its opening, the USPTO said the following: